Diversion of Benzodiazepines through Healthcare Sources by Ibanez, Gladys E. et al.
Nova Southeastern University 
NSUWorks 
CAHSS Faculty Articles Faculty Scholarship 
2-28-2013 
Diversion of Benzodiazepines through Healthcare Sources 
Gladys E. Ibanez 
Behavioral Science Research Institute 
Maria A. Levi-Minzi 
Nova Southeastern University, maria.leviminzi@nova.edu 
Khary K. Rigg 
Philadelphia VA Medical Center 
Angela D. Mooss 
Behavioral Science Research Institute 
Follow this and additional works at: https://nsuworks.nova.edu/shss_facarticles 
 Part of the Medicine and Health Sciences Commons, and the Sociology Commons 
NSUWorks Citation 
Ibanez, G. E., Levi-Minzi, M. A., Rigg, K. K., & Mooss, A. D. (2013). Diversion of Benzodiazepines through 
Healthcare Sources. Journal of Psychoactive Drugs, 45 (1), 48-56. https://doi.org/10.1080/ 
02791072.2013.764232 
This Article is brought to you for free and open access by the Faculty Scholarship at NSUWorks. It has been 
accepted for inclusion in CAHSS Faculty Articles by an authorized administrator of NSUWorks. For more 
information, please contact nsuworks@nova.edu. 
Diversion of Benzodiazepines through Healthcare Sources
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Abstract
Background—Benzodiazepines (BZ) are often diverted from legal sources to illicit markets at
various points in the distribution process which begins with a pharmaceutical manufacturer,
followed by distribution to healthcare providers, and finally, to the intended users. Little is known
about the extent of BZ diversion involving distribution points directly related to healthcare sources
(e.g., a script doctor) as opposed to points further down the distribution chain (e.g., street dealers).
The present study examines the scope of BZ diversion via mechanisms directly related to a
healthcare source. It examines the association between BZ dependence and the direct utilization of
particular healthcare-related diversion sources among a diverse sample of prescription drug
abusers in South Florida.
Method—Cross-sectional data were collected from five different groups of drug users:
methadone-maintenance clients (n = 247), street drug users (n = 238), public-pay treatment clients
(n = 246), private-pay treatment clients (n = 228), and stimulant using men who have sex with
men (MSM; n = 248).
Results—Findings suggest that those ages 26 to 35 years old, non-Hispanic White participants,
private-pay treatment clients, those who are insured, and those with higher incomes had higher
odds of utilizing healthcare diversion sources. Participants utilized a pharmacy as a diversion
source more than other healthcare sources of diversion, and the highest number of BZs were
obtained from doctor shopping compared to other diversion sources. Those who reported BZ
dependence also had 2.5 times greater odds of using a healthcare source to obtain BZs than those
who did not meet criteria for dependence.
Discussion—Prevention of BZ diversion through healthcare sources should include strategies to
reduce doctor shopping and diversion from pharmacies.
Keywords
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Benzodiazepine Use
Benzodiazepines (BZs) are a type of central nervous system depressant often used by
patients suffering from anxiety, acute stress attacks, and sleep disorders (National Institute
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on Drug Abuse 2005). Since benzodiazepines (BZs) have been shown to produce
dependence, some official recommendations indicate that BZs should be limited to only
brief terms (2–4 weeks) of use; however, despite these warnings, they continue to be
prescribed for long term use (Mehdi 2011); National Service Framework for Mental Health
1999). BZs are frequently prescribed medications with demonstrated abuse potential
(O’Brien 2005), as indicated by recent reports of emergency department visits documenting
an 89% increase in BZ involvement between 2004 and 2008 (Cai, et al. 2010). Moreover,
BZs are often abused when combined with other substances such as alcohol or opioids, and
they can slow heart rate and respiration to the point of death (O’Brien 2005), leading to
unintentional overdoses (Bohnert, Roeder, & Ilgen 2010).
The dangers of BZ abuse are particularly evident in Florida, where BZs were the second
most common drug present in decedents (after ethyl alcohol), and were found to play a
causal role (mostly in combination with other drugs) in the second highest number of deaths
which includes both intentional and unintentional deaths (after Oxycodone) (Florida
Department of Law Enforcement 2011). In 2009, the number of deaths involving BZs
increased 4% from the previous year, and BZs were involved in approximately three deaths
per day in Florida (Hall 2010). As the non-medical use of BZs continues to increase, it is
important to understand how abusers are illicitly acquiring these medications, as well as the
role that the healthcare system plays in their diversion. Increased knowledge in this area will
directly inform the development of programs and policies aimed at preventing BZ diversion
and abuse.
Prescription Drug Diversion
Prescription drug diversion involves obtaining prescription medications through illegal
means or the channeling of these drugs to the illicit marketplace, most often for the purpose
of using them in non-medical ways; that is, for enhancing pleasure or performance and/or
for moderating the effects of other drugs (Inciardi et al. 2007). For example, BZs may be
used to moderate the effects of drugs such as cocaine (Rigg & Ibañez 2010). Although all
prescription medications are legitimately and pharmaceutically manufactured, there are
different points in the distribution chain in which diversion may occur. Some of these
diversion points are directly related to a healthcare professional, such as when individuals
obtain BZs by going to multiple doctors or when they misuse legitimate prescriptions. Other
individuals may obtain their BZs from diversion sources that are not directly related to a
healthcare professional such as a street dealer or sharing with a friend or family member.
The diversion of all prescription medications from legal sources to illegal sources is
estimated to cost public and private medical insurers approximately $72.5 billion a year
(Coalition Against Insurance Fraud 2007). These losses include the cost of insurance
schemes such as fraudulent insurance claims for bogus prescriptions and phantom injuries,
as well as the estimated hidden cost of treatment for patients who develop actual medical
problems due to prescription drug abuse (Coalition against Insurance Fraud 2007). Most
experts now consider diversion to be one of the major drivers of the prescription drug abuse
epidemic in the United States (Inciardi, Surratt, Lugo, et al. 2007).
Although the abuse and diversion of BZs has been noted previously (DuPont 1988); Wilford
1991), much of the diversion literature has focused on either opioid medications specifically
(Cicero, et al. 2011), or has included numerous types of prescription medications grouped
together. Common mechanisms of diversion include both healthcare-related sources and non
healthcare-related sources. Health-care related sources of diversion refer to points in the
distribution of prescription medication that are directly related to a healthcare source, such
as: 1) ‘script’ doctors (i.e., the illegal sale of prescriptions by physicians); 2) ‘doctor
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shopping’ by individuals who visit numerous doctors to obtain multiple prescriptions; and,
3) pharmacy (i.e., undercounting of pills by pharmacy staff or pharmacist, theft by pharmacy
staff, fraud by staff or pharmacist). Non healthcare-related sources refer to points in the
distribution of prescription medication that are not directly related to healthcare sources.
These may include the following: 1) street buys/dealers; 2) theft (i.e., residential burglaries,
theft of prescription pad, forgery, or alteration of prescriptions); 3) sharing and trading with
friends; and 4) from a family member (Inciardi, et al. 2009a; Inciardi, et al. 2009b).
Healthcare diversion sources are often utilized by different types of drug abusing
populations. For example, opioid dependent persons entering methadone treatment programs
have reported using their main doctor to obtain a prescription, while the use of emergency
room doctors was less likely to be reported (Rosenblum, et al. 2007). The primary
healthcare-related diversion sources for opioid users include both legitimate (i.e., unknowing
doctors) and illegitimate medical practices (i.e., pill mills) (Cicero, et al. 2011). One
qualitative study exploring the different mechanisms of the diversion of prescription
medication among substance users in South Florida suggested that the role of pharmacies as
a diversion source is underestimated, and includes theft, employee pilferage, and fraud
(Inciardi, Surratt, Kurtz, et al. 2007). To date, most studies on prescription drug diversion
have either focused on the diversion of prescription drugs in general, or have centered on
opioids (Cicero, et al. 2011; Rigg, March, & Inciardi, 2010; Martins, et al. 2009; Inciardi, et
al. 2006). The diversion of benzodiazepines warrant specific attention, given that a
substantial percentage of unintentional deaths involve benzodiazepines. For example, one
study indicated that as many as 46% of unintentional deaths among benzodiazepine abusers
in West Virginia did not have valid prescriptions for them (Toblin, et al. 2010).
The Present Study
The purpose of this paper is to examine the most common diversion sources for
benzodiazepines (BZs), with a particular emphasis on healthcare sources. In addition, the
relationship between BZ dependence and diversion source is also examined. Specifically,
the present paper poses the following research questions: 1) To what extent are healthcare
and non-healthcare related diversion sources being used to obtain BZ’s? , 2) What individual
characteristics are related to the use of healthcare diversion sources to obtain BZs? , and 3)
are those who report BZ dependence more likely to utilize healthcare diversion sources than
those who do not report BZ dependence?
Method
Participants
To be eligible for the study, individuals needed to be 18 years of age or older, and report
abusing psychoactive prescription drugs at least 5 times within the last 90 days. For the
purposes of this study, prescription drug abuse was defined as follows: a) taking prescription
drugs without a legitimate prescription, or b) taking them in ways not prescribed by a
physician (i.e., overusing). Of the 1,503 total sample of prescription drug abusers, only the
BZ users were selected for further analyses (n = 1,207). Participants also had to meet one of
the following criteria to determine which study sub-sample they represented: 1) methadone-
maintenance treatment participants (n = 247) were currently enrolled in a methadone-
maintenance treatment program ; 2) street drug users (n = 238) must have used powder
cocaine, crack, or heroin 12 or more times in the past 30 days prior to interview date; 3)
public pay treatment clients (n = 246) were currently enrolled in a publicly funded/
subsidized drug treatment facility for fewer than 45 days prior to interview date, 4) private-
pay treatment clients (n = 228) were enrolled for fewer than 45 days in a substance abuse
treatment program that was paid by private insurance or personal funds, and finally 5) men
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who have sex with men (MSM; n = 248) who also reported using at least one stimulant
(cocaine, crack, ecstasy, or methamphetamine) three times in the past 90 days. For the
public and private pay treatment clients, their prescription drug use during the 90 days prior
to treatment entry was assessed. These samples were selected due to their high rates of
multiple substance use, and because previous studies demonstrated high rates of prescription
drug abuse among these groups of substance users (Brands, et al. 2004; Simoni-Wastila,
Ritter, & Strickler 2004).
Measures
For this study, the Global Appraisal of Individual Needs (GAIN; Dennis, et al. 2002) was
used to assess background characteristics and substance use. All scales and subscales of the
GAIN display good internal consistency (Cronbach alphas over .7). Cronbach alphas for all
scales and subscales were over .7
Background and Substance Use—Participants were assessed on several demographic
characteristics including age, gender, race/ethnicity (African-American, Hispanic/Latino,
White, Other), type of user group (methadone maintenance, public treatment, private
treatment, street users, MSM), income, and whether they had health insurance (yes/no).
Participants were asked to report the frequency and amount of specific benzodiazepines they
used non-medically in the last 90 days. Benzodiazepines included alprazolam, diazepam,
and clonazepam. All BZs were grouped for analysis. BZ dependence was assessed using the
GAIN-I subscale for substance dependence, which is based on Diagnostic Statistical Manual
(DSM-IV) criteria (7 items; Dennis, et al. 2002). Sample items for the dependence subscale
included ‘did you experience withdrawal symptoms from [a BZ] use?’ and ‘have you used
[a BZ] more or longer than you meant to?” Responses were dichotomous (yes/no). If the
participant endorsed 3 or more items specific to BZs, the participant met criteria for BZ
dependence.
Diversion Methods—Based on the existing literature, the authors developed a measure to
assess different types of diversion sources for each specific prescription drug misused by the
participant. Participants were asked which sources they used to divert and obtain
prescription drugs, how many times each source was used, and how many pills were
obtained within the last 90 days per diversion source. For the present analyses, we examined
only diversion sources used to obtain BZs. Diversion methods included sources that were
directly related to healthcare such as script doctors (i.e., a doctor that sells prescription),
doctor shopping (i.e., the user goes to multiple doctors for multiple prescriptions), and
pharmacy (i.e., undercounting pills by staff, employee pilferage, any staff theft), as well as
prescriptions from a regular doctor (i.e., the user misuses their own legitimate prescription).
These definitions were provided to the participant before asking them questions regarding
diversion. Non-healthcare diversion sources to obtain BZs such as theft, street dealer, family
members, and sharing/trading were also examined.
Procedures
A variety of purposive sampling strategies were used to locate and recruit study participants
which are described below.
Street Drug Users—Print media advertisements, handing out study cards, and the posting
of flyers were largely used to recruit active street drug users. A variation of respondent
driven sampling (RDS; Heckathorn, et al. 2002) to recruit street drug users was also used.
Each participant who completed an interview was also invited to refer anyone that they
thought would be eligible for the study. They were given a recruitment coupon to hand out
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to other interested participants with study contact information. Each participant was limited
to five referrals in an effort to minimize sample bias. Specific eligibility criteria were not
disclosed to the recruiters. Street drug users were provided a $10 monetary incentive for
each eligible referral that completed an interview.
Methadone Maintenance Clients—Assisted by methadone clinic staff, the research
staff identified and recruited methadone clients by posting flyers and handing out study
cards to individuals in the methadone clinics. Counselors at the clinics also handed out study
cards to clients, and each clinic provided space for interviews to be conducted. Methadone
clinic clients were sampled from various locations across South Florida including Miami,
Fort Lauderdale, and Fort Myers.
Public and Private Pay Treatment Clients—Treatment program staff identified new
clients who reported prescription drug abuse histories at intake, and contacted the research
team if the client was interested in participating. Flyers and study cards were also posted in
the public treatment centers. Interviews were conducted by research staff in a private room
at the treatment facility.
MSM—Participants were recruited via a combination of strategies including print media,
presentations at community-based organizations that serve the gay community, participant
referrals, and treatment centers. Interviews were conducted in private spaces in either our
research field offices, or in the participating treatment centers.
Screening and Interviewing
All participants were screened for eligibility before they were scheduled for a confidential
one-time interview. Street drug users, MSM, and methadone clients were screened over the
phone by research staff. For public and private-pay treatment clients, treatment staff
screened and identified eligible participants, and would coordinate with research staff to
schedule the interview.
Before administering the computer- assisted personal interview (CAPI), each participant was
re-screened to ensure eligibility. Once eligibility was confirmed, they were administered
informed consent. Participants were assured that participation was strictly confidential and
voluntary. After the consent form was signed, the CAPI interview was administered, which
assessed demographic information, mental and physical health, and drug use history.
Interviews lasted approximately 1- ½ to 2 hours; and after completing the interview, the
participant was given a $30 monetary incentive for their participation. All study protocols
and instruments were approved by the University of Delaware (predecessor institution for
the project) and Nova Southeastern University Institutional Review Boards.
Data Analysis
First, descriptive statistics were calculated for the total sample, and for each of the different
groups of substance users. Descriptive statistics were also calculated for the number of times
and the number of BZ pills that were obtained through each diversion source (both
healthcare and non-healthcare). Second, all the healthcare diversion sources (i.e., script
doctor, doctor shopping, pharmacist, regular doctor) were combined into an “any healthcare
diversion source” variable for further analysis. Cross-tabulations and univariate logistic
regressions were conducted to compare participants who reported using any healthcare
diversion source in the last 90 days to those who did not on various demographic
characteristics. Third, a multivariate logistic regression analysis was conducted to examine
the association between healthcare diversion sources and BZ dependence controlling for all
variables significant on the bivariate level. All demographic variables significant at the
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bivariate level were included as covariates in Step 1 of the model, followed by BZ
dependence in Step 2. A Hosemer-Lemeshow test was conducted to examine the goodness
of fit of the multivariate model.
Results
Descriptive statistics for the total sample as well as for each of the different user groups is
presented in Table 1. The mean age for the total sample was 35.3 (range: 18–59), and
participants were mostly male (63%). About half reported less than $1000 monthly income
on average (51%), and did not have current health insurance (52%). The racial/ethnic
breakdown of the sample included the following: 50% (n = 598) Non-Latino White, 23% (n
= 276) African-American, 23% (n = 277) Latino, and 4% (n = 56) Other. Of the 1,207 BZ
abusers, 759 (63%) reporting using one BZ, 378 (31%) used two BZs, and 70 (6%) used
three BZs. The most commonly used BZ was alprazolam (n = 1102, 91%) followed by
diazepam (n = 400, 33%), and clonazepam (n = 257, 21%).
As shown in Table 2, about 21% (n = 251) of the total sample had utilized at least one
healthcare related source to divert BZs in the last 90 days, with 35 participants utilizing
multiple healthcare related sources. The most commonly reported healthcare diversion
source was regular doctor, with 11% of the sample misusing their legitimate prescriptions.
The second most common healthcare diversion source was a script doctor, followed by
doctor shopping and pharmacy. Participants also reported how many times they used each
source specifically to obtain BZs and the total number of BZ pills obtained. The mean
number of times that each healthcare diversion source was used was higher for pharmacy
than any other healthcare source; and the median number of pills obtained was higher for
doctor shopping than any other healthcare source (Table 2).
We also examined similar data for non-healthcare diversion sources. As shown in Table 2, at
least one non-healthcare related source was utilized in the last 90 days by virtually the entire
sample (n = 1136; 94%), with 454 participants utilizing multiple non-healthcare related
sources. The most common non-healthcare diversion source was dealer/street buy. Sharing
and trading to obtain BZs was also more common than other sources of diversion such as
stealing from family members or non-family theft. Although non-healthcare sources were
reportedly utilized more often than healthcare sources for the overall sample, the median
number of pills obtained by these sources of diversion was generally lower than the number
of BZ pills obtained via healthcare sources. Dealers were the source used most often and the
source that produced the highest number of BZ pills among the non-healthcare sources.
Univariate logistic regressions were run to examine the associations between each of the
demographic variables and the use of healthcare diversion sources. Results indicated that
those between 26–35 years of age had 1.6 times greater odds of utilizing healthcare
diversion sources to obtain BZs compared to younger adults (Table 3). There were also
significant racial/ethnic differences, with African-American (OR = 0.39 [.26, .58], p < .001)
and Hispanic (OR = 0.51 [.35, .74], p < .001) participants having lower odds of utilizing
healthcare diversion sources compared to non-Hispanic Whites. In terms of user groups,
public treatment clients (OR = .47 [.31, .72], p < .001), methadone treatment clients (OR = .
52 [.34, .78], p < .002), MSM (OR = .59 [.39, .89]. p < .011), and street drug users (OR = .
23 [.14, .38], p < .001) reported lower odds of utilizing healthcare sources than private pay
treatment clients (reference group) to obtain BZs. Lastly, participants who reported higher
than $1000 monthly income (OR = 1.96 [1.47, 2.60], p < .008) or insurance coverage (OR =
1.89 [1.43, 2.51], p < .001) had greater odds of using healthcare diversion sources in the last
90 days than those with lower income or the uninsured.
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BZ dependence was assessed using the GAIN-I substance dependence subscale, with forty-
three percent (n = 521) of the sample meeting the criteria for dependence. Significant
variables in the univariate logistic regressions, along with BZ dependence, were then run in
a multivariate logistic regression model. Age, race, group, income, and insurance remained
significant predictors of using a healthcare diversion source in the last 90 days in the model.
After controlling for these covariates in step one, BZ dependence was entered in step two,
and those categorized as BZ dependent had 2.5 times greater odds of utilizing a healthcare
diversion source in the last 90 days compared to those who did not meet criteria for BZ
dependence (Table 4). Furthermore, a Hosmer-Lemeshow goodness of fit test conducted on
the multivariate model suggested that the model is a good fit, X2 = 11.42, df = 8, p < .179,
and the variables in the model accounted for approximately 14% of the variance in
healthcare diversion source (Nagelkerke R2 = .138).
Discussion
The present study examined the diversion mechanisms used to acquire BZs, the correlates of
utilizing healthcare diversion sources, and the association between diversion sources and BZ
dependence among a diverse sample of prescription drug abusers in South Florida. Results
indicated that those with higher income or medical insurance had higher odds of BZ
diversion through healthcare sources, which was expected given these participants’s access
to such sources for BZs. Furthermore, of the different groups sampled for this study, private
pay treatment clients were also more likely to use healthcare diversion sources than all other
user groups. Taken together, these findings emphasize how readily available BZs might be
for those with access to the health care system. This finding supports previous
recommendations for further research on the association between availability/supply with
abuse of prescription medication and its diversion (National Center on Addiction and
Substance Abuse at Columbia University [CASA] 2005), and highlights the need for more
oversight at this level.
The main findings indicate that healthcare diversion sources may be a more efficient way of
obtaining pills than non-healthcare sources. Interestingly, using a regular doctor as a
diversion source for BZs was reported by twice as many participants as was using a script
doctor (defined as a doctor that sells prescriptions), the second most common healthcare
source. Regular doctors accounted for as many BZ pills on average as did dealers/street buys
on the non-healthcare side. Although much attention has been focused on script doctors as a
diversion source, our findings suggest that attention on individuals diverting their legitimate
prescriptions is also warranted.
Although participants reported visiting healthcare sources far less often than non-healthcare
sources, more pills were obtained through these sources per visit. Additionally, those who
met the criteria for BZ dependence were also more likely than non-dependent individuals to
utilize healthcare sources of diversion. Our findings indicate that healthcare sources of
diversion have the potential to provide large quantities of pills sought by heavy or dependent
users, or dealers. In contrast, less frequent users may be more likely to use opportunistic
sources of diversion such as theft, dealers, or family members, which provide access to a
lower number of pills, possibly due to inconsistent supplies or access. Future studies should
examine the role that healthcare diversion sources may play in the progression from
therapeutic, legitimate BZ use to abuse and dependence. For example, are those who begin
using BZ’s for legitimate purposes more likely to develop BZ dependence compared to
those who begin BZ use illicitly, or vice versa? Are those who initially obtain BZ pills from
healthcare sources more likely to develop problematic BZ use than those who began
diverting BZ pills from non-healthcare sources?
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The role of pharmacies in the diversion of BZs remains unclear. Participants reported
obtaining BZs from pharmacies in similar quantities to those obtained through dealers.
Although diversion from pharmacies may generally encompass a number of activities and
mechanisms, concurrent qualitative data collected in the present study suggests that
pharmacy diversion most often involved pharmacy technicians, who tended to divert
relatively small amounts of BZ pills (Rigg, et al. 2012). Small thefts through undercounting
or shorting prescriptions, as well as failure to verify questionable or forged prescriptions
presented by their associates appear to be common mechanisms utilized by pharmacy techs
to divert medications (Rigg, et al., 2012). Future studies are needed to systematically assess
the role of pharmacy staff in the diversion of BZs and other controlled substances.
Limitations
This study has several strengths and limitations. The collection of cross-sectional data
prevented us from being able to establish causality between the independent and dependent
variables. However, these results do show a clear relationship between our variables of
interest. As with all self-report data, the possibility of recall bias should be considered.
Given that face-to-face interviewing was utilized as a means of data collection, social
desirability may have affected responses. As this was not a random sample, the
generalizability of the findings is limited. Strengths of the study include the following: to the
authors’ knowledge, this study is the first to investigate how prescription drug abusers, both
in and out of treatment, illicitly acquire BZ’s; this study examines diversion methods by BZ
use; and the study utilized CAPI interviews, which allows for more accuracy and privacy in
the data collection process (United Nations Statistics Division 2007).
Implications
Additional training of both physicians and pharmacists on prescription drug abuse and
diversion is needed. According to a recent survey of doctors and pharmacists, only 19% of
physicians received any training in identifying prescription drug diversion in medical
school, and less than half of pharmacists reported having any type of training or education
on prescription drug diversion since pharmacy school (CASA 2005). The same study found
that 25% of pharmacists reported that they do not regularly validate the prescribing doctor’s
DEA number when dispensing medication and despite the lack of training reported by both
physicians and pharmacists, over 80% stated they were confident that they could identify
prescription drug diversion (CASA 2005). Better education, training and supervision
standards for pharmacy techs with access to controlled medications are also urgently needed
(Rigg, Kurtz, & Surratt 2012; Traynor 2003).
In addition, physicians may need to implement procedures to track misuse of legitimate
prescriptions such as getting early refills by their clients. For example, if physicians suspect
diversion or abuse, they could ask patients to return to their office after a certain number of
days with their medication bottle to determine if the correct number of pills is in the bottle.
According to the CASA study (2005), only 23% of physicians actually conducted a pill
count when they suspected prescription drug abuse or diversion. Another suggestion might
be for physicians to set up a “one doctor, one treatment plan” for clients (Longo, et al.
2000). By having patients see the same doctor, early refills are more likely to be detected.
Furthermore, future studies should examine whether certain specific types of prescription
drugs (i.e., BZs vs. opioids) are diverted more often through healthcare sources than others.
Clearly, the schedule IV status of BZs would likely increase healthcare provider comfort
with prescribing these medications, however, the health consequences of BZ abuse and
dependence appear to warrant additional monitoring by physicians and other providers. For
example, treating BZs similar to schedule II drugs would restrict prescriptions to a 30 day
supply with no refills (Toblin, et al. 2010). However, this could make it difficult for patients
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with legitimate health issues to obtain needed prescriptions and subsequent refills. Another
recommendation in preventing BZ diversion and its subsequent miuse would be for
physicians to seek alternative treatments to BZ use such as cognitive behavioral therapy for
their patients (Toblin, et al. 2010).
In sum, and not surprisingly, those who have more access to healthcare systems (e.g., higher
income, insurance coverage) are more likely to utilize healthcare sources of diversion.
However, our findings also shed light on specific healthcare diversion sources that need
more research attention such as the use of a regular doctor’s legitimate prescription to divert
BZ, and diversion mechanisms within pharmacies. Our study contributes to the literature by
suggesting that how individuals obtain their BZs is related to dependence; specifically, those
who obtained BZs from healthcare sources were more likely to report BZ dependence.
Better monitoring systems within clinics and pharmacies in order for doctors, pharmacists,
and their staff to track the frequency of refills and frequent visits by individuals are needed
especially given the health consequences of BZ misuse, as well as training programs and
consultation for physicians, physician assistants, and nurse practitioners. Clearly, more
clinical work and research is needed to increase awareness of BZ abuse and diversion.
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Table 2
All Sources of Diversion Utilized in the last 90 days for Obtaining BZ (n = 1,207)
Sources of Diversion+ Number of Times
obtained BZs
Number of BZ pills Obtained in Last
90 Days
Healthcare-related (n = 251; 21%) Mean Median Mean Median
Regular Doctor (n =132; 11%) 4.2 3.0 169 144
Script Doctor (n = 90; 7.5%)* 5.3 3.0 275 180
Doctor Shopping (n = 41; 3.4%) * 7.0 4.0 672 360
Pharmacy (n = 31; 2.6%)* 24.4 6.0 184 100
Non-Healthcare (n = 1136; 94%)
Theft (n = 77; 6.4%)* 9.0 3.0 106 60
Dealer (n = 785; 65%)* 22.4 10.0 150 60
Family (n = 217; 18%) 13.6 4.0 *** ***
Sharing (n = 627; 52%)** 14.8 6.0 51 25
*
One outlier was excluded from analyses because it was above or below 3 standard deviations from the mean.
**
Outliers (n=12) were excluded from analyses if above or below 3 standard deviations from the mean.
+
Note: Sources of diversion are not exclusive. Participants can report more than one diversion source used.
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Table 4
Healthcare Diversion Sources Regressed on Background and BZ Dependence
Final Model B OR 95%CI p level
Step 1
Age .02 1.02 1.00, 1.03 .050
Race/Ethnicity .010
    Non-Hispanic White (ref)
    African-American −.64 0.53 .32, .86 .010
    Hispanic/Latino −.67 0.51 .34, .78 .002
    Other .26 .77 .37, 1.61 Ns
Group     .090
    Private, in treatment (ref)         
    Public, in treatment −.37 .69 .42, 1.13 ns
    Methadone −.59 .56 .35, 0.87 .011
    MSM −.14 .87 .53, 1.42 ns
    Street Users −.79 .45 .24, 0.85 .013
Income .49 1.63 1.20, 2.22 .002
Insurance .51 1.66 1.22, 2.26 .001
Step 2
BZ Dependence .93 2.54 1.88, 3.43 .001
Ref = reference group
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